While a significant proportion of patients with cancers harboring PI3K/Akt pathway alteration may be treated by Akt inhibitors, some of these patients may be insensitive to Akt inhibition due to primary or acquired drug resistance. This evidence concerns the gene PIK3CA and cancer.